Abstract:Purpose Glabridin is a major active constituent of Glycyrrhiza glabra which is commonly used in the treatment of cardiovascular and central nervous system (CNS) diseases. Recently, we have found that glabridin is a substrate of P-glycoprotein (PgP/MDR1). This study aimed to investigate the role of PgP in glabridin penetration across the blood–brain barrier (BBB) using several in vitro and in vivo models. Materials and Methods Cultured primary rat brain microvascular endothelial cells (RBMVECs) were used in the uptake, efflux and transcellular transport studies. A rat bilateral in situ brain perfusion model was used to investigate the brain distribution of glabridin. The brain and tissue distribution of glabridin in rats with or without coadministered verapamil or quinidine were examined with correction for the tissue residual blood. In addition, the brain distribution of glabridin in mdr1a (−/−) mice was compared with the wild-type mice. Glabridin in various biological matrices was determined by a validated liquid chromatography mass spectrometric method. Results The uptake and efflux of glabridin in cultured RBMVECs were ATP-dependent and significantly altered in the presence of a PgP or multi-drug resistance protein (Mrp1/2) inhibitor (e.g. verapamil or MK-571). A polarized transport of glabridin was found in RBMVEC monolayers with facilitated efflux from the abluminal (BL) to luminal (AP) side. Addition of a PgP or Mrp1/2 inhibitor in both luminal and abluminal sides attenuated the polarized transport across RBMVECs. In a bilateral in situ brain perfusion model, the uptake of glabridin into the cerebrum increased from 0.42 ± 0.09% at 1 min to 9.27 ± 1.69% (ml/100 g tissue) at 30 min and was significantly greater than that for sucrose. Co-perfusion of a PgP or Mrp1/2 inhibitor significantly increased the brain distribution of glabridin by 33.6−142.9%. The rat brain levels of glabridin were only about 27% of plasma levels when corrected by tissue residual blood and it was increased to up to 44% when verapamil or quinidine was coadministered. The area under the brain concentration-time curve (AUC) of glabridin in mdr1a (−/−) mice was 6.0-fold higher than the wild-type mice. Conclusions These findings indicate that PgP limits the brain penetration of glabridin through the BBB and PgP may cause drug resistance to glabridin (licorice) therapy for CNS diseases and potential drug-glabridin interactions. However, further studies are needed to explore the role of other drug transporters (e.g. Mrp1-4) in restricting the brain penetration of glabridin.

Brain Transport Profiles of Ginsenoside Rb1 by Glucose Transporter 1: in Vitro and in Vivo.

Ginsenoside Rb stimulates glucos

Neuroprotective Effects and Brain Transport of Ginsenoside Rg1

Ginsenoside Rg1 Attenuates Structural Disruption of the Blood-Brain Barrier to Protect the Central Nervous System in Ischemia/Reperfusion

Ginsenoside Rb1 Stimulates Glucose Uptake Through Insulin-Like Signaling Pathway in 3T3-L1 Adipocytes.

Ginsenoside Rb1 Exerts Neuroprotective Effects Through Regulation of Lactobacillus Helveticus Abundance and GABAA Receptor Expression

Role of P-glycoprotein in Limiting the Brain Penetration of Glabridin, An Active Isoflavan from the Root of Glycyrrhiza glabra

Transport behavior and efflux of Rg1 in rat pulmonary epithelial cells.

Ginsenoside Rb1 inhibits astrocyte activation and promotes transfer of astrocytic mitochondria to neurons against ischemic stroke

Ginsenoside Rg1 Nanoparticle Penetrating the Blood- Brain Barrier to Improve the Cerebral Function of Diabetic Rats Complicated with Cerebral Infarction

Enhanced Expression of the Blood-Brain Barrier GLUT1 Glucose Transporter Gene by Brain-Derived Factors

Ginsenoside Rb1 confers neuroprotection via promotion of glutamate transporters in a mouse model of Parkinson's disease.

Glucose Transporter 1, Distribution in the Brain and in Neural Disorders: Its Relationship with Transport of Neuroactive Drugs Through the Blood-Brain Barrier

Ginsenoside Rb1 protects hippocampal neurons from high glucose-induced neurotoxicity by inhibiting GSK3β-mediated CHOP induction

Dmd064881 1702..1710

Activating glucocorticoid receptor-ERK signaling pathway contributes to ginsenoside Rg1 protection against β-amyloid peptide-induced human endothelial cells apoptosis.

Influence of Blood Glucose on the Expression of Glucose Trans-Porter Proteins 1 and 3 in the Brain of Diabetic Rats.

Crosstalk among Oxidative Stress, Autophagy, and Apoptosis in the Protective Effects of Ginsenoside Rb1 on Brain Microvascular Endothelial Cells: A Mixed Computational and Experimental Study

Intranasal ginsenoside Rb1 targets the brain and ameliorates cerebral ischemia/reperfusion injury in rats.

Oral Absorption Of Ginsenoside Rb-1 Using In Vitro And In Vivo Models

Neuroprotective effects of ginsenoside Rb1 on transient cerebral ischemia in rats.